JPWO2020031936A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020031936A5 JPWO2020031936A5 JP2020535747A JP2020535747A JPWO2020031936A5 JP WO2020031936 A5 JPWO2020031936 A5 JP WO2020031936A5 JP 2020535747 A JP2020535747 A JP 2020535747A JP 2020535747 A JP2020535747 A JP 2020535747A JP WO2020031936 A5 JPWO2020031936 A5 JP WO2020031936A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- amino acid
- drug conjugate
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024043043A JP7892713B2 (ja) | 2018-08-06 | 2024-03-19 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A JP7900454B2 (ja) | 2018-08-06 | 2024-09-13 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018147582 | 2018-08-06 | ||
| JP2018147582 | 2018-08-06 | ||
| PCT/JP2019/030635 WO2020031936A1 (ja) | 2018-08-06 | 2019-08-05 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043043A Division JP7892713B2 (ja) | 2018-08-06 | 2024-03-19 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020031936A1 JPWO2020031936A1 (ja) | 2021-08-10 |
| JPWO2020031936A5 true JPWO2020031936A5 (cg-RX-API-DMAC7.html) | 2022-08-15 |
| JP7458981B2 JP7458981B2 (ja) | 2024-04-01 |
Family
ID=69414755
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535747A Active JP7458981B2 (ja) | 2018-08-06 | 2019-08-05 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024043043A Active JP7892713B2 (ja) | 2018-08-06 | 2024-03-19 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A Active JP7900454B2 (ja) | 2018-08-06 | 2024-09-13 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043043A Active JP7892713B2 (ja) | 2018-08-06 | 2024-03-19 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A Active JP7900454B2 (ja) | 2018-08-06 | 2024-09-13 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12497465B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3834843A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7458981B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210042120A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112512587A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019320336B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021001750A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3108754A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202190471A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202019487A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020031936A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250004902A (ko) * | 2017-08-23 | 2025-01-08 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법 |
| BR112021001750A2 (pt) * | 2018-08-06 | 2021-04-27 | Daiichi Sankyo Company, Limited | composição farmacêutica |
| IL288485B2 (en) * | 2019-05-29 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-TROP2 antibody conjugates - a drug for use in cancer treatment |
| JPWO2021200131A1 (cg-RX-API-DMAC7.html) * | 2020-03-30 | 2021-10-07 | ||
| US12605459B2 (en) | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| IL301921A (en) * | 2020-10-09 | 2023-06-01 | Daiichi Sankyo Co Ltd | Combining an antibody-drug conjugate and a selective 1PARP inhibitor |
| WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药(苏州)股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
| US20240058463A1 (en) * | 2020-12-18 | 2024-02-22 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| EP4393514A1 (en) * | 2021-08-24 | 2024-07-03 | Kunshan Xinyunda Biotech Co., Ltd. | Antibody-drug conjugate conjugated via breakable linker |
| US20240390512A1 (en) * | 2021-09-15 | 2024-11-28 | Daiichi Sankyo Company, Limited | Methods of treating chemotherapy-resistant cancer with an antibody-drug conjugate |
| CN119255825A (zh) * | 2022-05-24 | 2025-01-03 | 第一三共株式会社 | 抗-cdh6抗体-药物缀合物的剂量方案 |
| CN118955614B (zh) * | 2022-07-05 | 2025-12-30 | 上海药明合联生物技术有限公司 | 偶联连接子 |
| AU2024236246A1 (en) * | 2023-03-14 | 2025-10-30 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and VEGF inhibitor |
| JPWO2024204679A1 (cg-RX-API-DMAC7.html) * | 2023-03-31 | 2024-10-03 | ||
| WO2025002310A1 (zh) * | 2023-06-29 | 2025-01-02 | 石药集团巨石生物制药有限公司 | 抗体-药物偶联物及其用途 |
| WO2026128344A1 (en) * | 2024-12-09 | 2026-06-18 | Merck Sharp & Dohme Llc | Combinations for the treatment of cancer |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| AU2004224925C1 (en) | 2004-08-30 | 2011-07-21 | Biotest Ag | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| DE602005022928D1 (de) | 2004-11-30 | 2010-09-23 | Abgenix Inc | Antikörper gegen gpnmb und ihre verwendungen |
| AU2006262231B2 (en) | 2005-06-20 | 2013-01-24 | Psma Development Company, Llc | PSMA antibody-drug conjugates |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| NZ579644A (en) | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| JP6282232B2 (ja) | 2012-02-10 | 2018-02-21 | ユニバーシティー オブ メリーランド,ボルティモア | 抗体及びそのFcフラグメントの酵素化学的糖鎖改変 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| CN103239455A (zh) | 2012-12-24 | 2013-08-14 | 苏州大学 | 有协同治疗效果和高载药量的多组分纳米药物的制备方法 |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗cd98抗体−薬物コンジュゲート |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| US11185594B2 (en) | 2014-04-10 | 2021-11-30 | Daiichi Sankyo Company, Limited | (Anti-HER2 antibody)-drug conjugate |
| MX2017001946A (es) * | 2014-08-12 | 2017-06-19 | Novartis Ag | Conjugados de farmacos con anticuerpos anti-cdh6. |
| CA2979671C (en) | 2014-09-23 | 2020-03-10 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
| PT3313443T (pt) | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| CN122075735A (zh) | 2015-09-17 | 2026-05-26 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| AU2016366677A1 (en) * | 2015-12-09 | 2018-07-26 | Nantcell, Inc. | Compositions and methods for treatment of HER2 positive metastatic breast cancer |
| MY199595A (en) | 2016-03-02 | 2023-11-08 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| JPWO2018110515A1 (ja) | 2016-12-12 | 2019-10-24 | 第一三共株式会社 | 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
| SG11201906554RA (en) | 2017-01-17 | 2019-08-27 | Daiichi Sankyo Co Ltd | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| BR112021001750A2 (pt) * | 2018-08-06 | 2021-04-27 | Daiichi Sankyo Company, Limited | composição farmacêutica |
-
2019
- 2019-08-05 BR BR112021001750-0A patent/BR112021001750A2/pt unknown
- 2019-08-05 US US17/266,465 patent/US12497465B2/en active Active
- 2019-08-05 EP EP19847036.1A patent/EP3834843A4/en active Pending
- 2019-08-05 TW TW108127750A patent/TW202019487A/zh unknown
- 2019-08-05 CA CA3108754A patent/CA3108754A1/en active Pending
- 2019-08-05 CN CN201980052170.5A patent/CN112512587A/zh active Pending
- 2019-08-05 EA EA202190471A patent/EA202190471A1/ru unknown
- 2019-08-05 WO PCT/JP2019/030635 patent/WO2020031936A1/ja not_active Ceased
- 2019-08-05 KR KR1020217006189A patent/KR20210042120A/ko not_active Ceased
- 2019-08-05 JP JP2020535747A patent/JP7458981B2/ja active Active
- 2019-08-05 AU AU2019320336A patent/AU2019320336B2/en active Active
-
2024
- 2024-03-19 JP JP2024043043A patent/JP7892713B2/ja active Active
- 2024-09-13 JP JP2024158824A patent/JP7900454B2/ja active Active
-
2025
- 2025-09-04 AU AU2025226765A patent/AU2025226765A1/en active Pending
- 2025-11-11 US US19/385,360 patent/US20260139074A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020122034A5 (cg-RX-API-DMAC7.html) | ||
| JP2025041725A5 (cg-RX-API-DMAC7.html) | ||
| AU2019408811B2 (en) | Saponin conjugated to epitope-binding proteins | |
| JP7458981B2 (ja) | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP6328649B2 (ja) | 薬物−タンパク質コンジュゲート | |
| HRP20231609T1 (hr) | Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2 | |
| JP6473138B2 (ja) | 癌、特に前立腺癌を標的とする合成抗体模倣化合物(SyAM) | |
| JP2008546792A5 (cg-RX-API-DMAC7.html) | ||
| JP2020515578A5 (cg-RX-API-DMAC7.html) | ||
| JP2020524675A5 (cg-RX-API-DMAC7.html) | ||
| JP2013100314A5 (cg-RX-API-DMAC7.html) | ||
| JP2017528418A5 (cg-RX-API-DMAC7.html) | ||
| JP2018537975A5 (cg-RX-API-DMAC7.html) | ||
| JP2018509394A5 (cg-RX-API-DMAC7.html) | ||
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| JP2015500287A (ja) | 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法 | |
| RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
| JP2016511637A5 (cg-RX-API-DMAC7.html) | ||
| JP2012522512A5 (cg-RX-API-DMAC7.html) | ||
| EP3218414A1 (en) | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin | |
| JP2014508767A (ja) | 改善されたリンケージを有するアマトキシン複合体 | |
| JPWO2020027100A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2022102634A5 (cg-RX-API-DMAC7.html) | ||
| RU2018119683A (ru) | Сайт-специфические конъюгаты антитела к her2 и лекарственного средства | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения |